Citations 1
Bladder Cancer, Version 3.2024
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Buyyounouski, Mark K. , Chang, Paul, Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kaimakliotis, Hristos Z. , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Michalski, Jeff M., Montgomery, Jeffrey S., Patterson, Anthony, Peyton, Charles C. , Preston, Mark A. , Sexton, Wade J. , Stewart, Tyler F. , Sundi, Debasish , Tollefson, Matthew K. , Wright, Jonathan L. , Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chan, Kevin , Chang, Sam S. , Chang, Paul, Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.
Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 216-225
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.